Introduction
The neu protooncogene (also known as HER-2 or c-erbB2) encodes a 185-kDa transmembrane receptor tyrosine kinase (p185) that belongs to the epidermal growth factor (EGF 1 ) receptor family (Bargmann et al., 1986b; Coussens et al., 1985; Yamamoto et al., 1986) . Overexpression of neu is found in many human cancers, including breast (McCann et al., 1991; Slamon et al., 1987) , ovarian (Berchuck et al., 1990; Hung et al., 1992; Tyson et al., 1991) , lung (Weiner et al., 1990) and oral cancers (Hou et al., 1992; Xia et al., 1997) , and is correlated with poor survival for patients who have these cancers (Baak et al., 1991; Berchuck et al., 1990; Slamon et al., 1989; Toikkanen et al., 1992) . The transformation potential of this protein is well-documented. Point mutation-activated neu exhibits strong transforming ability, in both cultured ®broblasts and animal models (Bargmann et al., 1986a; Hung et al., 1986 Hung et al., , 1989 Muller et al., 1988; Yu and Hung, 1991) . Overexpression of normal neu can also induce neoplastic transformation (Di Fiore et al., 1987; Di Marco et al., 1990) . Overexpression and point mutation enhance the tyrosine kinase activity of this receptor (Samanta et al., 1994; Sternberg and Gullick, 1989; Weiner et al., 1989) , and point mutation makes cells escape from cell cycle regulation (Kiyokawa et al., 1995 ; both these eects are believed to play crucial roles in neu oncogenesis. Although multiple downstream targets of neu have been identi®ed, the signaling pathway for cellular transformation is not yet completely de®ned (Hunter, 1997) .
Recent evidence indicates that the mitogen-activated protein kinase (MAPK) pathway is involved in oncogenesis (Hunter, 1997) . The immediate downstream components leading to MAPK activation by receptor tyrosine kinases (RTKs) include Shc and Grb2. Shc adaptor proteins are the cytoplasmic substrates of activated RTKs, such as EGF receptor and neu (Ricci et al., 1995; Segatto et al., 1993) . They have three isoforms (p46, p52 and p66) which share a SH2 domain in the C-terminus, an adjacent collagen-homology region (CH1) and, in their N-terminal region, a newly identi®ed phosphotyrosine binding domain (PTB) (Blaikie et al., 1994; Kavanaugh and Williams, 1994; van der Geer and Pawson, 1995) . p66 Shc also harbors a unique collagen-homology region (called the CH2 domain) (Migliaccio et al., 1997) . Shc proteins are phosphorylated and form stable complexes with activated RTKs through the interaction of their SH2 and/or PTB domains with the RTKs (Blaikie et al., 1994; Kavanaugh and Williams, 1994; Pelicci et al., 1992 Pelicci et al., , 1995 Segatto et al., 1993; van der Geer and Pawson, 1995; van der Geer et al., 1995) . Upon being receptor activated, phosphorylated Shc proteins associate with the Grb2 adaptor protein (Clark et al., 1992; Lowenstein et al., 1992) through binding of the Grb2 SH2 domain to the Shc tyrosinephosphorylation residues Y317 (Salcini et al., 1994) and Y239/240 (Gotoh et al., 1996 (Gotoh et al., , 1997 van der Geer et al., 1996) . Grb2 is constitutively complexed with SOS (Gale et al., 1993; Li et al., 1993; Rozakis-Adcock et al., 1993) , a guanylnucleotide exchange factor for Ras, in the cytoplasm. The membrane relocalization of SOS by recruitment of the Grb2-SOS complex causes Ras activation (Bon®ni et al., 1992; Simon et al., 1991) . Ras activation, in turn, stimulates the downstream kinase cascade, the Raf-1/MEK/MAPK pathway. A number of studies support a direct role of Shc in Ras regulation. Shc overexpression leads to transformation of NIH3T3 cells Salcini et al., 1994) and dierentiation of PC12 cells (RozakisAdcock et al., 1992) . Transformation of NIH3T3 cells by Shc overexpression depends on the presence of Y317 of Shc, one of the Grb2 binding sites. The dominant-negative Ras protein, RasN17, blocks the dierentiation of PC12 cells caused by Shc overexpression. Microinjection of Shc antibodies into cells blocks mitogenic response to growth factors (Roche et al., 1996; Sasaoka et al., 1994) . In addition, overexpression of Shc, but not the Y317-site mutated Shc, enhances proliferative response and MAPK activation by EGF (Fukazawa et al., 1996; Gotoh et al., 1997; Migliaccio et al., 1997) , GM-CSF , thrombin (Chen et al., 1996) , and integrin (Wary et al., 1996) .
Rat neu that is activated by point mutation (V664E) in the transmembrane domain has constitutive tyrosine kinase activity (called p185*) and transforms NIH3T3 cells (Bargmann et al., 1986a) . Our previous studies showed that Shc phosphorylation and Shc-Grb2 complex are correlated with transformation induced by p185* (Xie et al., 1995a) . Also, Shc is constitutively phosphorylated in human neu-overexpressing breast cancer cells (Xie and Hung, 1996) . A dominant-negative mutant of Grb2, which impairs the association of endogenous Grb2 with Shc and as a result inhibits Ras activation, induces reversal of the transformed phenotypes caused by p185* (Xie et al., 1995b) . These ®ndings suggest that Shc might be responsible for the p185*-induced oncogenesis through its regulation of the MAPK pathway. However, our previous work also suggest that stable binding of Shc to p185* may not be necessary for p185*-induced transformation as a cterminal truncated p185* (truncated p185*) virtually loses its ability to bind with Shc, but still fully retains its ability to transform NIH3T3 cells and induces ShcGrb2 complex formation. This observation does not rule out the possibility that physical association between Shc and truncated p185* (p185*, too) may still be required for p185*-mediated cellular transformation in vivo yet this association is not stable enough to be detected by the in vitro co-immunoprecipitation procedure. One way to address this issue is to generate a Shc mutant that could bind to p185*, but not Grb2. Thus, the Shc mutant might prevent endogenous Shc from binding to p185* and impair p185* signal transmission. If endogenous Shc-p185* binding is critical for cell transformation, such Shc mutant might inhibit transformation capacity of p185*. To this end, we constructed a Shc mutant (called ShcDCH1) that lacked the Grb2 docking site Y317 (by deleting the CH1 domain) but retained the p185 binding domains, PTB and SH2. We found that B104-1-1 cells' (p185*-transformed NIH3T3 cells) transforming phenotypes were suppressed significantly by expression of ShcDCH1. We also observed that ShcDCH1 could bind to p185*, not to Grb2. However, stable expression of ShcDCH1 in B104-1-1 cells did not interfere with the association of endogenous Shc with p185* and the MAPK activation mediated by p185* was not aected either. These ®ndings suggest that ShcDCH1 suppresses the transformation induced by p185* through a MAPK-independent pathway.
Results and discussion
ShcDCH1 (Shc mutant deleted CH1 domain) was able to suppress the transforming activity of p185* When we initiated this project, Y317 in Shc was the only known site for Grb2 binding. Transformation of NIH3T3 cells by Shc overexpression required the presence of this residue (Salcini et al., 1994) . Based on this, to make a Shc mutant defective in Grb2 binding, we eliminated Y317 from Shc by deleting the most part of CH1 domain (called ShcDCH1, Figure  1a ). To clarify whether this Shc mutant could impair the oncogenic signaling caused by p185*, we performed both focus-forming assay and soft-agar assay. We contransfected LTR erbB-2 glu (point mutation-activated human neu) with either ShcDCH1 or its vector backbone (as a control) into Rat1 cells. Two days after transfection, cells were split into three equal portions. One portion was applied for focus formation, one portion for soft agar growth and the other portion for G418 selection to monitor the transfection eciency. As shown in Figure 1b and c, compared with the vector control, expression of ShcDCH1 could dramatically reduce the focus formation induced by p185*. Furthermore, p185*-induced anchorage-independent growth was also inhibited by the presence of ShcDCH1 (Figure 1b) . Transfection either ShcDCH1 (data not shown) or vector alone (Figure 1c ) into Rat1 cells did not result in any foci. These data indicate that ShcDCH1 is able to impair the oncogenic ability of p185*.
Establishment of ShcDCH1 transfectants
To determine whether the expression of ShcDCH1 could suppress the cellular transformation phenotypes caused by p185*, we transfected expression vector encoding ShcDCH1 or vector backbone into B104-1-1 cells. The expression of the ShcDCH1 in the transfectants was examined by Western blot analysis using monoclonal antibody against the HA1 epitope, which was tagged to the expression vector (Gishizky et al., 1995) . The detected ShcDCH1 product was about 38 kDa, consistent to the expected size ( Figure  2 ). We picked up two clones, ShcDCH1-13 and ShcDCH1-18, which exerted the highest expression levels among the tested clones, and a transfectant pool containing approximate 40 colonies for further studies. Anti-HA1 Western blot indicated that ShcDCH1 was highly expressed in these two clones but at a much lower level in the transfectant pool ( Figure 2 ). To compare the expression level of ShcDCH1 with endogenous Shc, the same membrane was stripped and reprobed with the anti-Shc polyclonal antibody. This Western blot showed the levels of ShcDCH1 expression in the two transfectant clones were comparable to that of endogenous Shc (Figure 2) . However, the anti-Shc antibody used here was produced by immunization with the peptide of the Shc protein corresponding to positions 359 ± 473, and ShcDCH1, which was generated by deleting amino acids 250 ± 379, retained only part of the epitopes. Thus, the antibody might not recognize the mutant as eciently as it does the endogenous wild-type Shc. Therefore, we believe that the actual expression level of ShcDCH1 could be higher than what was indicated by the relative intensities shown in the Figure, and that the level of ShcDCH1 expression was likely to be higher than that of endogenous Shc in these two ShcDCH1 transfectants.
To evaluate the level of p185* protein in the stable transfectants, immunoblot analysis using antibody against p185 was performed. The expression levels of p185* were comparable between the parental B104-1-1 cells and its transfectants (Figure 2 ). Anti-phosphotyrosine Western blot analysis also revealed that the autophosphorylation levels of p185* were the same among these cells (data not shown). Thus, transfection of ShcDCH1 did not aect p185* expression and tyrosine phosphorylation, consistent with the notion that Shc is a downstream target of p185*.
Decreased transformation phenotypes in ShcDCH1 transfectants
To evaluate the transformation phenotypes of ShcDCH1 transfectants, soft agar colony formation assays were performed to compare the anchorageindependent growth abilities of the parental cells and the ShcDCH1 transfectants. As shown in Figure 3a , the transformation potency of ShcDCH1-13 and ShcDCH1-18 were dramatically weakened compared with parental cells, whereas the ShcDCH1-pool cells were only moderately aected. Transformation suppression was correlated with the level of ShcDCH1 expression in these transfectants. The transformation suppression observed in soft agar colony assays was not due to decreased growth rates of ShcDCH1 transfectants: the Figure 1 (a) Schematic representations of ShcDCH1 (Shc mutant from which the CH1 domain has been deleted) and ShcWT (wildtype p52 Shc). Both of them were constructed in an HA1-tagged expression vector, pCGN-Bam. (b) ShcDCH1 was able to impair the transforming capability of p185*. LTR erbB2 glu (neu*, 1 mg) was cotransfected with pCI-neo (2 mg) and 20 mg of ShcDCH1 or vector (pCGN-Bam) into Rat1 cells. Two days after transfection, the cells were split into three portions. One portion were applied for focus forming, one portion for soft agar growing and the other portion for G418 selection. The resulting number of foci or colonies in soft agar was corrected for transfection eciency by dividing by the number of G418-resistant colonies from the same transfection. The left panel is the result from focus-forming assay and the right panel is from soft agar assay. neu* stood for the transforming LTR erbB2 glu. (c) Representative experiment from focus-forming assay growth rates of parental B104-1-1 cells and the transfectants were comparable (data not shown).
To con®rm the reduced in vitro transformation phenotype in ShcDCH1-13 and ShcDCH1-18 cells, we performed a microfocus-forming assay to measure these two cells' activity for loss of contact inhibition (Reardon et al., 1994) . Compared with the vector control, both transfectants formed fewer foci ( Figure  3b ), indicating that ShcDCH1 expression blocked the activity for loss of contact inhibition. In addition, morphological studies indicated that ShcDCH1-13 and ShcDCH1-18 exhibited morphological reversal (data not shown). This was evident by loss of the spindleshaped morphology and the bright, refractile cell borders that characterize vector control and B104-1-1 cells. Thus, all the data from soft agar colony assay, microfocus-forming assay and morphological studies showed that ShcDCH1 inhibits in vitro transformation phenotypes induced by p185*.
To further assess whether ShcDCH1 expressed protein can aect the in vivo transformation phenotype of B104-1-1, a tumorigenicity assay in nude mice was performed. The tumor growth from the two ShcDCH1 transfectants, ShcDCH1-13 and ShcDCH1-18 was decreased compared with the growth from the vector-alone transfectant (Figure 3c ). The results of this assay were consistent with the ®ndings from the two in vitro assays mentioned above. Taken together, our data indicate that the transformation phenotypes of B104-1-1 can be suppressed by stable expression of the ShcDCH1 mutant.
The association of ShcDCH1 with p185* did not interfere with the interactions among p185*, endogenous Shc and Grb2
To investigate the molecular mechanism of the transformation suppression caused by ShcDCH1, ®rst co-immunoprecipitation and Western blot analyses to determine whether ShcDCH1 associated with p185* or Grb2 were used. ShcWT transfectant (expresses the HA1-tagged p52 Shc in B104-1-1 cells) as a positive control and vector backbone transfectant as a negative control in this experiment were used. Anti-HA1 antibody was used to separately precipitate ShcDCH1 and ShcWT along with their associated proteins. As shown in Figure 4a , p185* was detected in the anti-HA1 immunoprecipitations for both ShcDCH1 and ShcWT, not for the vector transfectant. However, Grb2 was detected in only the ShcWT transfectant, not in ShcDCH1 and vector (Figure 4a ). Western blotting with anti-HA1 antibody indicated that comparable amounts of ShcDCH1 and ShcWT were precipitated from ShcDCH1-13 and ShcWT transfectants, respectively. These data together demonstrate that ShcDCH1 is able to associate with p185* at least as well as wildtype Shc, but its association with Grb2 is undetectable.
Recently, two novel tyrosine-phosphorylation sites in Shc (Y239/240) have also been found to mediate interaction with Grb2 in response to EGF or IL3 stimulation (Gotoh et al., 1996 (Gotoh et al., , 1997 van der Geer et al., 1996) . Thus, Shc has three major phospho-tyrosine residues (Y239/240 and Y317). Site-directed mutagenesis studies showed that mutation of either Y317 or Y239/240 in Shc only partially destroys the Grb2 binding. In our study, ShcDCH1 (amino acids 250 ± 379 deleted) still retained Y239/240, but its association with Grb2 was undetectable (Figure 3a) , suggesting that Y239/240 might not be able to be phosphorylated in ShcDCH1. To test this possibility, we performed an a-HA immunoprecipitation followed by Western blot using a-phospho-Tyr antibody. As shown in Figure 4b , both in the absence and presence of tyrosine phosphatase inhibitor, the tyrosine phosphorylation level in ShcDCH1 (upper panel) was signi®cantly decreased compared with that in wild type Shc after normalization to their protein level (bottom panel). These data strongly suggest that Y239/240 is not able to be phosphorylated well in ShcDCH1 and this might explain why ShcDCH1 was defective in Grb2 binding.
Detecting the association of p185* with ShcDCH1 triggered us to ask whether the interaction of p185* with endogenous Shc was inhibited in ShcDCH1 transfectants. To address this issue, anti-p185 immunoprecipitates were analysed by immunoblotting with anti-p185 and anti-Shc antibodies (Figure 4c ). Immunoblotting with anti-p185 showed equal amounts of p185* were precipitated in vector and ShcDCH1-13 transfectants. The amount of endogenous p52 Shc coprecipitated by anti-p185 antibody in ShcDCH1-13 was also the same as that in the vector-alone transfectants. In a longer exposure (Figure 4d ), we also observed that equal amounts of p66 Shc was coprecipitated with p185* between these two cell lines and that ShcDCH1 was associated with p185* in ShcDCH1-13 cells. We repeated this experiment in another transfectant, ShcDCH1-18, and the result was the same (data not shown). These results suggest that the ShcDCH1-p185* association does not interfere with the binding of endogenous Shc to p185*. Next we wanted to know whether Grb2 binding to p185* was aected by the ShcDCH1-p185* association. We analysed anti-p185 immunoprecipitates by anti-Grb2 Western blotting. The results revealed that equal Figure 2 Immunoblot analysis of ShcDCH1 expression in ShcDCH1 transfectants. B104-1-1 is a transformed NIH3T3 cell line expressing the point mutation-activated HER-2/neu, p185*. Vector, ShcDCH1-pool, ShcDCH1-13 and ShcDCH1-18 are stable transfectants derived from B104-1-1 cells, expressing either vector alone or ShcDCH1. Cell lysates (25 mg) from the indicated cell lines were subject to 4 ± 20% gradient SDS ± PAGE. After transfer, the top portion of the membrane was incubated with a monoclonal anti-p185 antibody, c-neu-Ab3; the lower part was probed with 12CA5, a monoclonal antibody speci®c to the HA1 tag, or was stripped and reprobed with anti-Shc polyclonal antibody amounts of Grb2 were precipitated by p185* in the vector and ShcDCH1 transfectants, suggesting that ShcDCH1 did not aect the Grb2-p185* association (Figure 4c ). The endogenous Shc-Grb2 complex was also not impaired by the ShcDCH1, which was con®rmed by analysing anti-Shc immunocomplex by anti-Grb2 Western blotting (data not shown). Taken together, these data suggest ShcDCH1 expression does not aect the interactions among p185*, Grb2, and endogenous Shc.
The MAPK/Elk activation mediated by p185* was not impaired in ShcDCH1 transfectants
We originally expected that stable expression of ShcDCH1 in B104-1-1 cells might inhibit the interaction of p185* with endogenous Shc, and therefore suppressed downstream signal pathway and resulted in loss of transformed phenotypes. However, the results described above indicate that stable expression of ShcDCH1 does not in¯uence the interaction of p185* with endogenous Shc or Grb2, but it still clearly suppressed the transformation. Since MAPK, which is thought to be a downstream target of Shc/Grb2-mediated pathway, has been shown to play a critical role in cellular transformation (Hunter, 1997) , the above results raise two interesting possibilities: (1) ShcDCH1 might impair MAPK activation through pathways other than Grb2-Shc complex or (2) ShcDCH1 might suppress p185*-induced transformation through a MAPK-independent pathway. To clarify it, MAPK kinase activity in ShcDCH1 transfectants using an immunocomplex kinase assay was examined. It was found MAPK activation mediated by p185* remained the same in vector and ShcDCH1 transfectants (Figure 5a ). The transactivation activity of Elk-1, a downstream eector of MAPK, by transient transfection was further evaluated. Elk-1 has been shown to be a substrate of MAPK and its transcriptional activity can be stimulated by MAPK activation (Marais et al., 1993) . In accordance with the results of the MAPK assay, the Elk transactivation activity mediated by p185* was comparable in the vector and ShcDCH1 transfectants (Figure 5b) . Thus, ShcDCH1 expression does not impair the transmission of the p185* signal to MAPK/Elk, which is consistent with the result that the p185*-Shc association was not aected.
In summary, we demonstrated that the expression of ShcDCH1 in B104-1-1 cells is able to suppress their transformation phenotypes using soft agar colony formation assay, microfocus-forming assay, and tumorigenicity assay. This ®nding strongly indicates that Shc mediates the p185* oncogenic pathway. Coimmunoprecipitation and Western blot analyses demonstrated that the association among p185*, Grb2, and endogenous Shc is not interfered with by ShcDCH1 binding to p185*. In addition, we showed that MAPK activation mediated by p185* is not impaired by ShcDCH1 expression in B104-1-1 cells. Collectively, these results suggest that ShcDCH1 suppresses the transformation phenotype through a MAPK independent pathway and Shc may play other roles in addition to MAPK pathway.
Y317 is the ®rst tyrosine residue shown to be important for Grb2 binding in Shc protein (Salcini et al., 1994) . More recent studies demonstrates that Y239/ 240 are also involved in Grb2 association (Gotoh et al., 1996 (Gotoh et al., , 1997 van der Geer et al., 1996) . When this project was initiated, Y317 was the only known site for Grb2-Shc binding. Based on this, the Shc mutant (ShcDCH1) which lacks Y317, but still retains Y239/ 240 was made. However, interestingly, our studies show that ShcDCH1 is not able to associate with Grb2 ( Figure 4a ). Our data also provide a reasonable interpretation for this observation: Y239/240 cannot Figure 4 (a) ShcDCH1 mutant was associated with p185* but not Grb2. Indicated cells at 80% con¯uence were serum-starved overnight and harvested. Cell extracts (500 mg) from dierent cell lines were used in immunoprecipitation with anti-HA1 antibody. ShcWT is a transfectant that expresses the HA-tagged wild-type p52 Shc in B104-1-1 cells. Immunocomplexes (left lanes) or 25 mg of lysates (right lanes) from each cell line were separated by a 4 ± 20% gradient SDS ± PAGE (IP, immunoprecipitation; W, Western blot). The membrane was cut into three pieces after transfer. The top, middle, and bottom portions were probed with anti-p185, anti-HA1, and anti-Grb2 antibody, respectively. IgG represented the immunoglobin, which came from the antibody used for immunoprecipitation. (b) ShcDCH1 exhibited a much lower level of tyrosine phosphorylation compared with wild type Shc. ShcWT and ShcDCH1-13 cells were treated with or without Na 3 VO 4 (tyrosine phosphatase inhibitor) for 4 h at concentration of 1 mM before harvesting. 150 mg lysate from ShcWT and 450 mg lysate from ShcDCH1-13 were used for a-HA immunoprecipitation. The immunoprecipitates were subjected to Western blot using a-phospho-tyrosine antibody (PY20) (upper panel). The phosphotyrosine level of ShcDCH1 was much lower than that of ShcWT even three fold excess of lysates were loaded. IgG signal shown in this panel came from the a-HA antibody used for immunoprecipitation. To show the protein level, the same membrane was stripped and reprobed with a-HA antibody (bottom panels). (c) Endogenous p185*-Shc or p185*-Grb2 complex was not interfered with in ShcDCH1 transfectants. Cell extracts (1 mg) from the indicated cell lines were used in immunoprecipitation with the anti-p185 antibody, c-neu-Ab4. Normal mouse serum (NMS) was used as the negative control. Immunocomplexes or 50 mg lysates from each cell line were separated by an 8% SDS ± PAGE. The ®lter was cut into three pieces after transfer. The top portion was probed with anti-p185 antibody, the middle with anti-Shc antibody, and the bottom with anti-Grb2 antibody. (d) ShcDCH1 and p66 (pointed by *) were able to co-precipitate with p185*. This was a longer exposed ®lm from the experiment of Figure 3C (middle panel) be phosphorylated well in ShcDCH1 (Figure 4b) . As the deletion in ShcDCH1 is very close to Y239/240, we suspect that the deletion might cause a steric position change of these two residues that abrogates their phosphorylation by p185*.
In this report, we did not answer the question we originally intended to address: whether physical association between Shc and p185* is required for p185*-mediated transformation. However, we observed that the Shc mutant blocks the transformation without impairing the endogenous p185*-Shc-Grb2 complex and MAPK activity. This interesting observation indicates that Shc may be involved in other signal pathway(s) critical for cellular transformation in addition to MAPK pathway. The mechanism by which ShcDCH1 suppresses the cellular transformation by p185* remains to be elucidated. ShcDCH1 was able to associate with p185* as well as the wild-type Shc did (Figure 4a ). However, it does not interfere with the binding of endogenous Shc to p185* ( Figure  4c ). One possible explanation for this is that p185* is excessive in B104-1-1 cells that contain multiple copies of the transfected neu oncogene (Hung et al., 1986) . Other groups also recently found that SH2 domain of ShcC, a member of Shc family, is capable of inhibiting EGFr transformation without aecting EGFr-ShC association, which is consistent with our observation (personal communication from Drs John P O'Bryan and Channing J Der). The mechanism of ShcDCH1 action might be to target those basal-level proteins which are important for p185* transformation, such as PI 3-kinase (Harrison-Findik et al., 1995) , Src (McGlade et al., 1992) , or other unknown molecules. Some evidence indicates that PI 3-kinase and Src pathways, which can be activated by p185*, may play a role in p185* oncogenesis (Hunter, 1997) . It has also been suggested that Shc might modulate PI 3-kinase or Src signal; this suggestion is based on the observations that Shc can serve as a substrate of activated Src and can complex with PI 3-kinase, although it is not fully clear which domain in Shc is involved in this interaction. If this is the case, ShcDCH1 might also impair the transformation by other oncogenes for which PI 3-K and Src pathways are important. Accordingly, ShcDCH1 would become a more general transformation suppressor and might have broader application value. Further systematic investigation are required to elucidate which pathway is involved in the transformation suppression caused by ShcDCH1. However, our current study, clearly indicates that the Shc mutant from which the CH1 domain has been deleted, suppresses the transformation induced by p185* and that this suppression is mediated through a MAPK-independent pathway.
Materials and methods

Cell lines and culture
B104-1-1 cells are transformed NIH3T3 cells generated by transfection with the point mutation-activated neu oncogene, which was originally derived from a neuro/ glioblastoma cell line (Padhy et al., 1982) . Cells were grown in Dulbecco's modi®ed Eagle's medium/Ham's F-12 medium supplemented with 10% calf serum. Cell lysates (250 mg) from the indicated cell lines, which were serum starved overnight before harvesting, were used in immunoprecipitation with anti-ERK1 antibody. One set of ERK1 immunoprecipitates was used in an in vitro kinase assay by incubation with MBP, as described in Materials and methods. Samples were separated by SDS ± PAGE and visualized on a PhosphorImager. Another set of immunoprecipitated ERK1 was subjected to Western blotting with an anti-ERK1 antibody used to determine the protein level. Images were quantitated by densitometry. Finally, the MAPK activity was normalized to the protein level. The graph shows the average kinase activity in three separate experiments. A representative experiment is shown below the graph (ICK, immunocomplex kinase assay). (b) Comparable Elk transactivation activities in B104-1-1 cells and ShcDCH1 transfectants. Indicated cells were transiently cotransfected with Gal4-Elk expression vector and Gal4-luc reporter gene. b-gal was used to monitor the transfection eciency. The cells were serum starved 2 days after transfection, and then harvested. The luciferase activity and b-gal activity were measured. The data shown here are average from three independent experiments Plasmids ShcWT is the wild-type form of p52 Shc which was cloned from a HeLa cell cDNA library. ShcDCH1 is a CH1 domain deletion mutant of ShcWT (amino acids 250 ± 379 deleted). The cDNAs encoding ShcWT and ShcDCH1 are constructed in the expression vector pCGN-Bam, which contains the hygromycin-resistant gene as a selection marker (Gishizky et al., 1995) . LTR erbB2 glu is the expression vector of activated human neu whose amino acid 659 is mutated from Val to Glu (Segatto et al., 1988) . pCI-neo is from Promega which carries G418 resistant gene.
Establishment of stable transfectants of Shc deletion mutants
B104-1-1 cells were transfected with the plasmid pCGNBam or the expression vectors encoding ShcDCH1 or ShcWT by the calcium phosphate precipitation methods described previously (Suen and Hung, 1990) . Vector, ShcDCH1-13/ShcDCH1-18 and ShcWT are stable transfectants derived from B104-1-1 cells, expressing vector alone, ShcDCH1, and ShcWT, respectively.
Colony formation assay in soft agar
Experiments were carried out as previously reported, with minor modi®cation (Xie et al., 1995b) . Cells (1000 per well for ShcDCH1 stable cell lines) were plated in a 24-well plate for this assay.
Focus-forming assay
Experiments were performed as described previously with some modi®cations (Xie et al., 1995b) . LTR erbB2 glu (1 mg) was cotransfected with pCI-neo (2 mg) and 20 mg of ShcDCH1 or vector pCGN-Bam into Rat1 cells in 10-cm plates. Two days after transfection, cells were split into three portions. One portion was cultured in duplicated plates using regular calf serum medium for 3 ± 4 weeks for focus forming, while the second portion were grown in medium with G418. The rest of the cells were applied for soft agar assay by growing in four wells of the 6-well plates. The resulting number of foci or colonies in soft agar was corrected for transfection eciency by dividing by the number of G418-resistant colonies from the same transfection. Shown here is the average of three individual experiments. Standard deviation is shown by an error bar.
Microfocus-forming assay
The assays were performed as described previously (Reardon et al., 1994) . Two hundred and ®fty cells from each cell line were combined separately with 1.0610 6 NIH3T3 cells and cultured in 10-cm dishes for 2 weeks. Foci were counted after staining with crystal violet (1% crystal violet, 20% ethanol in H 2 O).
Tumorigenicity assay
The assays were carried out as previously described (Chen et al., 1997) . Viable cells (5610 5 ) were subcutaneously injected into the right and left¯anks of female homozygous nu/nu mice. Tumor formation was scored at days 7, 9 and 11 after injection, and tumor volumes were estimated as the product of three-dimensional caliper measurements.
Antibodies
The monoclonal antibodies c-neu-Ab3 and c-neu-Ab4 were from Oncogene Science. The anti-phosphotyrosine monoclonal antibody (PY20) was from UBI. The rabbit anti-Shc polyclonal antibody and the mouse anti-Grb2 monoclonal antibody were purchased from Transduction Laboratories.
The monoclonal anti-HA1 epitope antibody (12CA5) was from Boehringer Mannheim. Rabbit anti-ERK1 polyclonal antibody (c-16) was from Santa Cruz Biotechnology.
Immunoprecipitation and Western blotting
Cells at 80% con¯uence were serum starved overnight and lysed in the lysis buer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EGTA, pH 8.0, 100 mM NaF, pH 8.0, 10% glycerol, 1.5 mM MgCl 2 , 1% Triton X-100, and 1 mM Na 3 VO 4 ) for anti-p185 immunoprecipitation. Cell extracts from the lysis buer (50 mM HEPES, pH 7.5, 150 mM NaCl, 50 mM ZnCl 2 , 50 mM NaH 2 PO 4 , 50 mM NaF, 2 mM EDTA, 1 mM Na 3 VO 4 , 1% NP-40, 2 mM PMSF) were used for anti-HA1 Na 3 VO 4 antibody immunoprecipitation. Immunoprecipitation and Western blotting were performed according to the supplier's speci®cations. Antibody was detected by enhanced chemiluminescence (Amersham).
In vitro MAPK activity assay Subcon¯uent cell lines were serum starved overnight and harvested in a lysis buer (25 mM NaCl, 25 mM Tris pH 7.5, 1% Nonidet P-40, 10 mM sodium pyrophosphate, 0.5 mM EGTA, 1 mM sodium vanadate, 10 mM NaF, 10 nM okadaic acid, and 1 mM PMSF). Lysates were immunoprecipitated with the anti-ERK1 antibody. One set of ERK1 immunoprecipitates was assayed for kinase activity by incubation with MBP in the presence of [g-32 P]ATP, as described previously (Alessi et al., 1995) . Samples were separated by SDS ± PAGE and visualized on a PhosphorImager (Molecular Dynamics). A second set of ERK1 immunoprecipitates was used for protein-level determinations by Western blotting with an anti-ERK antibody. Images were quantitated by densitometry.
Transactivation activity assay of Elk
Cells were cultured in 35-mm dishes and transiently cotransfected with 100 ng of Gal4-Elk fusion construct, 1 mg of Gal4-luc reporter gene (kindly provided by CJ Der) (Khosravifar et al., 1996) , and 0.6 mg of b-gal plasmid using Lipofectamine Reagent (GIBCO ± BRL). After transfection, the cells were serum starved for 2 days, and then harvested. Luciferase activity was measured according to the procedure provided by Promega.
Abbreviations b-gal, b-galactosidase; CH1, collagen-homology domain 1; EGF, epidermal growth factor; ERK, extracellular signalregulated kinase; GM-CSF, granulocyte-macrophage colony-stimulating factor; HA1, hemagglutinin epitope; IL-3, interleukin-3; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; p185*, point mutationactivated neu-encoded protein; PI 3-kinase, phosphatidylinositol 3-kinase; PTB, phosphotyrosine binding domain; RTK, receptor tyrosine kinase; SDS ± PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; ShcDCH1, CH1 domain deletion mutant of Shc; ShcWT, wild-type p52 Shc
